Colorectal cancer
C28 – C65
- C28: Comparisons between two techniques to determine epidermal growth factor receptor protein and gene expression in colorectal cancers
- C29: Novel mutations in the K-Ras oncogene: implications for personalised medicine in the treatment of colorectal cancer
- C30: Curcumin formulated with phosphatidylcholine (Meriva) enhances anti-tumour efficacy of oxaliplatin in a nude mouse colorectal cancer xenograft model.
- C31: A phase I study of pazopanib in combination with FOLFOX 6 or CapeOx in the first line treatment of metastatic colorectal cancer.
- C32: Use and transferability of a computerised decision support system for the colorectal multidisciplinary meeting
- C33: The prognostic implications of improved detection of venous invasion in resected colorectal cancer specimens.
- C34: The detailed molecular analysis of formalin-fixed paraffin embedded (FFPE) wild-type or mutant KRAS colorectal primaries with the aims of identifying transcripts and pathways of relevance to Cetuximab sensitivity and/or KRAS mutational status
- C35: Pathways of Oxaliplatin/5-Fluorouracil resistance in colorectal cancer
- C36: Cost-effectiveness of pre-prescription pharmacogenetic testing for irinotecan
- C37: A simple inflammation based score measured prior to surgery predicts outcome following adjuvant chemotherapy for colorectal cancer.
- C38: Chemoradiotherapy (CRT) for anal cancer: routine prophylactic inguinal node irradiation may not be needed
- C39: Comparison of capecitabine and intravenous 5-flourouracil with preoperative pelvic radiation for rectal cancer
- C40: The potential impact of colo-rectal cancer prevention and screening in the UK
- C41: NFKB1 and NFKBIA promoter polymorphisms in relation to cancer risk and clinicopathological factors in colorectal cancer patients
- C42: Influence of antioxidant status and biological ageing in patients with colorectal cancer
- C43: Accelerated biological ageing in colorectal carcinoma
- C44: Trends in laparoscopic colorectal tumour resections across England between 1998 and 2006
- C45: Hopefulness predicts resilience after hereditary colorectal cancer genetic testing in Hong Kong Chinese: results of a longitudinal study
- C46: Anxiety and depression in colorectal cancer patients: results from the PICT programme
- C47: Inhibition of pyruvate dehydrogenase kinase activity promotes apoptosis in colorectal cancer cells
- C48: DNA polymerases as potential therapeutic targets for DNA mismatch repair deficient cancers
- C49: Fbxw7 (hCDC4) E3-ubiquitin ligase receptor: lineage potential and its commitment to cancer
- C50: Similarities in epigenetic changes between ulcerative colitis-associated colorectal carcinogenesis and sporadic tumourigenesis
- C51: T lymphocyte changes during intestinal tumourigenesis in the ApcMin/+ mouse model
- C52: Crypt stem cells as the cells-of-origin of intestinal cancer
- C53: rs10795668 located at 10p14 is associated with colorectal cancer risk in Han Chinese
- C54: Anemia does not affect the plasma clearance of chemotherapeutic drugs in cancer patients
- C55: Investigation of FLCN mutations in renal and colorectal cancers
- C56: Identification of potential colorectal cancer biomarkers using 2D gel electrophoresis analysis
- C57: Topoisomerase-1 (Topo1) as a predictive and prognostic factor in chemotherapy for advanced colorectal cancer (aCRC)
- C58: Simple and reliable method for mutation detection in formalin-fixed tissue using High-resolution Melting analysis (HRM)
- C59: Altered Sirtuin expression in colorectal cancer
- C60: A spliced variant of RNA-binding protein TIA-1, regulates VEGF expression in colon cancer
- C61: Hypermethylation of sFRP1: a potential screening marker for colorectal cancer?
- C62: Hypermethylation of APC, ESR1 and CDH13 as a marker for colorectal cancer
- C63: Lactate dehydrogenase-5 is an independent prognostic factor in colorectal cancer: implications for future therapies
- C64: Kras mutation status as biomarker for response to TRAIL treatment in colorectal cancer
- C65: Expression of p53 family of proteins and VEGF in colorectal carcinoma and adenoma: correlation with survival and response to treatment
